Business
Issue of Shares - Replacement
Issue of Shares - Replacement.
About this update from Renalytix Plc
[{"type":"text","content":"\n\nThe following amendment has been made to the 'Issue of Shares' announcement released on 17 July 2023 at 07:00 under RNS No 1495G\n \nThe correct figure for the principal remaining under the convertible bond after the settlement of the repayment is $15.90 million.\n \nAll other details remain unchanged.\n \nThe full amended text is shown below.\n \nRenalytix plc\n(\"Renalytix\" or the \"Company\")\n \nIssue of Shares\n \nLONDON and SALT LAKE CITY - July 17, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), announces the repayment of $1.06 million of the Company's convertible bond, further details of which were announced on 31 March 2022. The repayment is being made through the issue of 526,211 American Depositary Shares (\"ADS\").\n \nAfter settlement of the repayment, the principal remaining under the convertible bond will be reduced by $1.06 million to $15.90 million.\n \n1,052,422 new ordinary shares of £0.0025 each in the capital of the Company (the \"Ordinary Shares\") will be issued to settle the conversion of 526,211 ADSs, with each ADS representing two Ordinary Shares.\n \nAn application has been made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 1,052,422 new Ordinary Shares to trading on AIM will become effective on, or around, 8am UK time on 19 July 2023 (\"Admission\"). The new Ordinary Shares will rank pari passu with the existing Ordinary Shares of the Company.\n \nTotal voting rights\nFollowing Admission, the Company will have 94,833,900 Ordinary Shares in issue with each share carrying the right to one vote. The Company has no Ordinary Shares held in treasury. The total number of voting rights in the Company following Admission will therefore be 94,833,900.\n \nFor further information, please contact:\n \n\n\n\nRenalytix plc\n\n\nwww.renalytix.com\n\n\n\n\nJames McCullough, CEO\n\n\nVia Walbrook PR\n\n\n\n\n\n\n\n \n\n\n\n\nStifel (Nominated Adviser, Joint Broker)\n\n\nTel: 020 7710 7600\n\n\n\n\nAlex Price / Nicholas Moore / Nick Harland / Samira Essebiyea\n\n\n \n\n\n\n\n\n\n\n \n\n\n\n\nInvestec Bank plc (Joint Broker)\n\n\nTel: 020 7597 4000\n\n\n\n\nGary Clarence / Shalin Bhamra\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR Limited\n\n\nTel: 020 793...